MELLOW PHARMA
ActiveSummary
MELLOW PHARMA has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €245,952 and a net result of €101,364. Equity is growing by about 24% per year across the filed financial years. Its solvency ranks better than 34% of 39,131 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
16-07
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Highest result from 2021 to 2025net €101,364 ▲54.4%
Operating result €142,288, net result €101,364, both a record.
29-08
NBB filing
Annual accounts filed
financial year 2024 · micro format · 29 days late
2024
29-07
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-12
Financial
Weakest financial yearnet €48,402 ▼47.7%
Net result drops to €48,402, the lowest in the series; recovery starts the following year.
31-12
Financial
Equity above €200,000equity €245,952 ▲23.9%
A profit in every financial year since 2021 builds equity to €245,952.
26-07
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
2022
31-12
Financial
Equity above €150,000equity €198,550 ▲83.7%
A profit in every financial year since 2021 builds equity to €198,550.
30-08
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format · 30 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.